Heart failure & cardiomyopathies

Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials

JAMAPublished Systematic review and meta-analysis of randomised trials

Pooled resultResult — go to the resultRelative risk 0.80 95% CI 0.69–0.94

Authors' conclusion

The findings from this meta-analysis support TTR gene silencing for ATTR-CM.

Study context

Population
Patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Participants
2,086 patients · 2 RCTs
Comparison
TTR gene-silencing therapy vs placebo
Outcome
Composite of:
  • All-cause mortality
  • Recurrent CV events
Methodological detailsfixed-effects, placebo-controlled phase 3 trials
  • Fixed-effects
  • Placebo-controlled phase 3 trials

Pooled result

As reported in the abstract

Relative risk

0.80

95% CI 0.69–0.94

P = 0.006

Gene-silencing therapy vs Placebo
RR 0.80 (95% CI 0.69–0.94); P = 0.006

Further pooled results

OutcomeEstimate
All-cause deathHR 0.74 (95% CI 0.61–0.91)
Time to first all-cause death or CV eventsHR 0.77 (95% CI 0.67–0.89)
Primary end point, by baseline stabilizer use (subgroup) — Gene-silencing therapy vs Placebo · no background stabilizerRR 0.69 (95% CI 0.57–0.85)
Primary end point, by baseline stabilizer use (subgroup) — Gene-silencing therapy vs Placebo · concomitant stabilizer at baselineRR 0.97 (95% CI 0.77–1.23)
OutcomeEstimate
6-minute walk distance · no evidence of between-trial heterogeneityplacebo-corrected difference +22.2 m (95% CI 14.3–30.0)
KCCQ-Overall Summary Score · no evidence of between-trial heterogeneitydifference +4.5 (95% CI 2.7–6.2)
  • Primary end point, by baseline stabilizer use (subgroup): P for heterogeneity = .03

Primary end point, by baseline stabilizer use (subgroup)

Similar heterogeneity for functional capacity and health status

Original publication

Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials. JAMA. Published 30 August 2026. doi:10.1001/jama.2026.17246

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.